{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:54:42Z","timestamp":1793328882137,"version":"4.5.0"},"reference-count":20,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Botulinum Toxin injections into salivary glands (SG) up to a total dose of 100 units IncobotulinumtoxinA (IncoA) represent the treatment of choice for sialorrhea. However, BTX might also protect SG against sialotoxic radioligand cancer therapies. The radioligand Actinium-225-PSMA effectively targets Prostate Cancer (PCa) metastases but inevitably destroys SG due to unintended gland uptake. A preliminary case series with regular-dose IncoA failed to reduce SG PSMA-radioligand uptake. We therefore increased IncoA dosage in combination with transdermal scopolamine until a clinically relevant SG PSMA-radioligand uptake reduction was achieved. Ten consecutive men with metastasized PCa refractory to all other cancer therapies received gradually increasing IncoA dosages as part of a compassionate use PSMA-radioligand-therapy trial. The parotid gland received six and the submandibular gland three injection points under ultrasound control, up to a maximum of 30 units IncoA per injection point. A maximum total dose of 250 units IncoA was applied with up to 170 units per parotid and 80 units per submandibular gland. Treatment was well tolerated and all side-effects were non-serious. The most frequent side-effect was dry mouth of mild severity. No dysphagia, facial weakness, chewing difficulties or systemic side-effects were observed. SG injections with IncoA up to a total dose of 250 units are safe when distributed among several injection-points under ultrasound control by an experienced physician. These preliminary findings lay the basis for future trials including BTX as major component for SG protection in established as well as newly emerging radioligand cancer therapies.<\/jats:p>","DOI":"10.3390\/toxins14010064","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T20:49:21Z","timestamp":1642452561000},"page":"64","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Safety of High-Dose Botulinum Toxin Injections for Parotid and Submandibular Gland Radioprotection"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2518-2715","authenticated-orcid":false,"given":"Joerg","family":"Mueller","sequence":"first","affiliation":[{"name":"Department of Neurology, Vivantes Klinikum Spandau, Neue Bergstrasse 6, D-13585 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Langbein","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Technical University of Munich, Klinikum rechts der Isar, Ismaninger Strasse 22, D-81675 M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Curanosticum Wiesbaden, Deutsche Klinik f\u00fcr Diagnostik, Aukammallee 33, D-65191 Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Baum","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Curanosticum Wiesbaden, Deutsche Klinik f\u00fcr Diagnostik, Aukammallee 33, D-65191 Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40120-019-00155-6","article-title":"Therapy of sialorrhea with Botulinum Neurotoxin","volume":"8","author":"Jost","year":"2019","journal-title":"Neurol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.117.203539","article-title":"Targeted Alpha Therapy of mCRPC with 225Actinium-PSMA-617: Swimmer-Plot analysis suggests efficacy regarding duration of tumor control","volume":"59","author":"Kratchowil","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.2967\/jnumed.118.214379","article-title":"Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies","volume":"59","author":"Langbein","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13550-021-00770-1","article-title":"Muscarinic inhibition of salivary glands with glycopyrronium bromide does not reduce the uptake of PSMA-ligands or radioiodine","volume":"11","author":"Mohan","year":"2021","journal-title":"EJNMMI Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2967\/jnumed.118.212449","article-title":"Long-Term Effects of Radioiodine Treatment on Salivary Gland Function in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma","volume":"60","author":"Selvakumar","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_6","first-page":"103","article-title":"PSMA-Positivit\u00e4t der Speicheldr\u00fcsen in der Ga-68-PSMA-PET: Spielt N\u00fcchternheit eine Rolle?","volume":"59","author":"Huang","year":"2020","journal-title":"Nuklearmedizin"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/ijos.2013.82","article-title":"Botulinum Toxin A inhibits salivary secretion of rabbit submandibular gland","volume":"5","author":"Shan","year":"2013","journal-title":"Int. J. Oral Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/jop.12887","article-title":"Effects of chronic treatment with botulinum toxin type A in salivary glands of rats: Histological and immunohistochemical analyses","volume":"48","author":"Regueira","year":"2019","journal-title":"J. Oral Pathol. Med."},{"key":"ref_9","first-page":"161","article-title":"Effekte eines Zyklus Actinium-225-PSMA-617 (AcPSMA) auf die Speicheldr\u00fcsen\u2014Vorl\u00e4ufige Ergebnisse","volume":"59","author":"Feuerecker","year":"2020","journal-title":"Nuklearmedizin"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"L\u00f6fgren, C.D., Wickstr\u00f6m, C., and Christersson, C. (2012). A systemic review of methods to diagnose oral dryness and salivary gland function. BMC Oral Health, 12.","DOI":"10.1186\/1472-6831-12-29"},{"key":"ref_11","first-page":"1128","article-title":"A quantitative test for xerostomia","volume":"28","author":"Kohler","year":"1985","journal-title":"The Saxon test, an oral equivalent of the Schirmer test. Arthritis Rheum."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5535\/arm.2017.41.1.51","article-title":"Accuracy of ultrasound-guided and non-ultrasound-guided botulinum toxin injection into cadaver salivary glands","volume":"41","author":"So","year":"2017","journal-title":"Ann. Rehab. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/mdc3.12881","article-title":"Localization of Salivary Glands for Botulinum Toxin Treatment: Ultrasound Versus Landmark Guidance","volume":"7","author":"Loens","year":"2020","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1007\/s00415-019-09681-7","article-title":"Effective long-term treatment with incobotulinum (Xeomin\u00ae) without neutralizing antibody induction: A monocentric, cross-sectional study","volume":"267","author":"Hefter","year":"2020","journal-title":"J. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Samadzadeh, S., Uerer, B., Brauns, R., Rosenthal, D., Lee Ji Albrecht, P., and Hefter, H. (2020). Clinical implications of difference in antigenicity of different Botulinum Neurotoxin Type A preparations: Clinical Take-Home Messages from our Research Pool and Literature. Toxins, 12.","DOI":"10.3390\/toxins12080499"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/toxins5020249","article-title":"Long-term efficacy and safety of botulinum toxin injections in dystonia","volume":"5","author":"Jankovic","year":"2013","journal-title":"Toxins"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kaufmann-Janette, J., Cox, S.E., Dayan, S., and Joseph, J. (2021). Botulinum Toxin Type A for Glabellar Frown Lines: What impact of Higher Doses on Outcomes?. Toxins, 13.","DOI":"10.3390\/toxins13070494"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA","volume":"3","author":"Feuerecker","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.2967\/jnumed.118.222307","article-title":"First Clinicopathologic Evidence of a Non\u2013PSMA-Related Uptake Mechanism for 68Ga-PSMA-11 in Salivary Glands","volume":"60","author":"Rupp","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bjp.0707375","article-title":"Intraglandular application of botulinum toxin leads to structural and functional changes in rat acinar cells","volume":"152","author":"Teymoortash","year":"2007","journal-title":"Br. J. Pharmacol."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/1\/64\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:02:45Z","timestamp":1760133765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/1\/64"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["toxins14010064"],"URL":"https:\/\/doi.org\/10.3390\/toxins14010064","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]}}}